

Resource Summary Report

Generated by [dkNET](#) on Sep 20, 2026

PerCP/Cyanine5.5 anti-human CD45

RRID:AB_2566352

Type: Antibody

Proper Citation

BioLegend Cat# 368504, RRID:AB_2566352

Antibody Information

URL: http://antibodyregistry.org/AB_2566352

Proper Citation: BioLegend Cat# 368504, RRID:AB_2566352

Target Antigen: CD45

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: PerCP/Cyanine5.5 anti-human CD45

Description: This monoclonal targets CD45

Target Organism: human

Clone ID: Clone 2D1

Antibody ID: AB_2566352

Vendor: BioLegend

Catalog Number: 368504

Alternative Catalog Numbers: 368503

Record Creation Time: 20231110T035153+0000

Record Last Update: 20260829T143018+0000

Ratings and Alerts

No rating or validation information has been found for PerCP/Cyanine5.5 anti-human CD45.

No alerts have been found for PerCP/Cyanine5.5 anti-human CD45.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 19 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Tebas P, et al. (2026) Clinical Trial Results Provide the Rationale to Protect Dual HIV-specific T Cells with a Signaling-Defective HIV Fusion Inhibitor. Molecular therapy : the journal of the American Society of Gene Therapy.

Li F, et al. (2026) Ferritin aggregation cell engager for CAR T avidity engineering against refractory leukemias. Cell, 189(7), 1942.

Wagoner ZW, et al. (2025) Systems immunology analysis of human immune organoids identifies host-specific correlates of protection to different influenza vaccines. Cell stem cell, 32(4), 529.

Shukla D, et al. (2025) CAR Binders Affect CAR T-cell Tonic Signaling, Durability, and Sensitivity to Target. Cancer immunology research, 13(6), 867.

Shukla D, et al. (2025) Optimal pairing of binder and co-stimulatory domains improves dual CART cell efficacy. Molecular therapy : the journal of the American Society of Gene Therapy.

Konno Y, et al. (2024) Two-step evolution of HIV-1 budding system leading to pandemic in the human population. Cell reports, 43(2), 113697.

Yamagishi M, et al. (2024) Quantitative live-cell imaging of secretion activity reveals dynamic immune responses. iScience, 27(6), 109840.

Chen Y, et al. (2024) Spatiotemporal single-cell analysis decodes cellular dynamics underlying different responses to immunotherapy in colorectal cancer. Cancer cell, 42(7), 1268.

Bakbak E, et al. (2024) Icosapent ethyl modulates circulating vascular regenerative cell content: The IPE-PREVENTION CardioLink-14 trial. Med (New York, N.Y.), 5(7), 718.

Della Volpe L, et al. (2024) A p38 MAPK-ROS axis fuels proliferation stress and DNA damage during CRISPR-Cas9 gene editing in hematopoietic stem and progenitor cells. Cell reports. Medicine, 5(11), 101823.

Zhang J, et al. (2024) Pyroptotic T cell-derived active IL-16 has a driving function in ovarian endometriosis development. *Cell reports. Medicine*, 5(3), 101476.

Wang X, et al. (2024) Cell-intrinsic PD-L1 ablation sustains effector CD8⁺ T cell responses and promotes antitumor T cell therapy. *Cell reports*, 43(2), 113712.

Lu L, et al. (2023) STING signaling promotes NK cell antitumor immunity and maintains a reservoir of TCF-1⁺ NK cells. *Cell reports*, 42(9), 113108.

Tang F, et al. (2023) A pan-cancer single-cell panorama of human natural killer cells. *Cell*, 186(19), 4235.

Wang X, et al. (2021) GPR34-mediated sensing of lysophosphatidylserine released by apoptotic neutrophils activates type 3 innate lymphoid cells to mediate tissue repair. *Immunity*, 54(6), 1123.

Zaman R, et al. (2021) Selective loss of resident macrophage-derived insulin-like growth factor-1 abolishes adaptive cardiac growth to stress. *Immunity*, 54(9), 2057.

Golebski K, et al. (2021) Induction of IL-10-producing type 2 innate lymphoid cells by allergen immunotherapy is associated with clinical response. *Immunity*, 54(2), 291.

Aso H, et al. (2020) Multiomics Investigation Revealing the Characteristics of HIV-1-Infected Cells In Vivo. *Cell reports*, 32(2), 107887.

Yamada E, et al. (2018) Human-Specific Adaptations in Vpu Conferring Anti-tetherin Activity Are Critical for Efficient Early HIV-1 Replication In Vivo. *Cell host & microbe*, 23(1), 110.